Haematopoietic stem cell transplantation in adult soft-tissue sarcoma

• Verfasst von: Heilig, Christoph E. [VerfasserIn]
• Verfasst von: Badoglio, Manuela [VerfasserIn]
• Verfasst von: Labopin, Myriam [VerfasserIn]
• Verfasst von: Fröhling, Stefan [VerfasserIn]
• Verfasst von: Secondino, Simona [VerfasserIn]
• Verfasst von: Heinz, Jürgen [VerfasserIn]
• Verfasst von: Nicolas-Virelizier, Emmanuelle [VerfasserIn]
• Verfasst von: Blaise, Didier [VerfasserIn]
• Verfasst von: Korenbaum, Clément [VerfasserIn]
• Verfasst von: Santoro, Armando [VerfasserIn]
• Verfasst von: Verbeek, Mareike [VerfasserIn]
• Verfasst von: Krüger, William H. [VerfasserIn]
• Verfasst von: Siena, Salvatore [VerfasserIn]
• Verfasst von: Passweg, Jakob R. [VerfasserIn]
• Verfasst von: Di Nicola, Massimo [VerfasserIn]
• Verfasst von: Rifón, Jose [VerfasserIn]
• Verfasst von: Dreger, Peter [VerfasserIn]
• Verfasst von: Köhl, Ulrike [VerfasserIn]
• Verfasst von: Chabannon, Christian [VerfasserIn]
• Verfasst von: Pedrazzoli, Paolo [VerfasserIn]
• Titel: Haematopoietic stem cell transplantation in adult soft-tissue sarcoma
• Titelzusatz: an analysis from the European Society for Blood and Marrow Transplantation
• Verf.angabe: Christoph E. Heilig, Manuela Badoglio, Myriam Labopin, Stefan Fröhling, Simona Secondino, Jürgen Heinz, Emmanuelle Nicolas-Virelizier, Didier Blaise, Clément Korenbaum, Armando Santoro, Mareike Verbeek, William Krüger, Salvatore Siena, Jakob R. Passweg, Massimo Di Nicola, Jose Rifón, Peter Dreger, Ulrike Koehl, Christian Chabannon, Paolo Pedrazzoli
• E-Jahr: 2020
• Jahr: 23 October 2020
• Umfang: 8 S.
• Fussnoten: Gesehen am 22.04.2021
• Titel Quelle: Enthalten in: ESMO open
• Ort Quelle: [London] : Elsevier, 2016
• Jahr Quelle: 2020
• Band/Heft Quelle: 5(2020), 5, Artikel-ID e000860, Seite 1-8
• ISSN Quelle: 2059-7029
• DOI: doi:10.1136/esmoopen-2020-000860
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: high-dose chemotherapy
• Sach-SW: soft-tissue sarcoma
• Sach-SW: stem cell transplantation
• K10plus-PPN: 1755704771

Abstract

Background - The role of high-dose chemotherapy with autologous stem cell transplantation (ASCT) in the treatment of soft-tissue sarcoma (STS) remains an unsettled issue. Prospective clinical trials failed to prove a benefit of the procedure but were limited by small and heterogeneous patient cohorts. Thus, it is unknown if ASCT may be a valuable treatment option in specific patient subgroups. - Methods - The purpose of this study was to investigate the value of ASCT according to histological subtype in STS patients who were registered in the European Society for Blood and Marrow Transplantation database between 1996 and 2016. - Results - Median progression-free (PFS) and overall survival (OS) in the entire cohort of 338 patients were 8.3 and 19.8 months, respectively, and PFS and OS at 5 years were 13% and 25%, respectively. Analysis of outcomes in different subgroups showed that younger age, better remission status before transplantation and melphalan-based preparative regimen were predictive of benefit from ASCT, whereas histology and grading had no statistically significant impact. - Conclusions - Outcomes after ASCT compared favorably to those of recent trials on conventional chemotherapies and targeted therapies in STS, including histology-tailored approaches. ASCT, thus, should be reinvestigated in clinical trials focusing on defined patient subgroups.